首页|HER2低表达年轻早期乳腺癌患者临床病理特征及预后分析

HER2低表达年轻早期乳腺癌患者临床病理特征及预后分析

扫码查看
目的 比较不同人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)表达水平年轻早期乳腺癌患者的临床病理特征及预后情况,分析HER2低表达年轻早期乳腺癌患者的临床病理特征及预后.方法 收集2016年6月至2018年6月期间于西安交通大学第一附属医院乳腺外科接受治疗的1 723例乳腺癌患者,根据HER2表达情况将患者分为HER2阴性、低表达和高表达3组,比较3组患者的临床病理特征,同时分析HER2表达情况与患者预后的关系.结果 HER2阴性患者共512例,HER2低表达患者共748例,HER2高表达患者共463例.3组患者的临床病理特征分析结果显示,3组不同HER2表达水平乳腺癌患者在婚姻状况、绝经状态、家族史、单独T分期(肿瘤大小)、单独M分期(远处转移情况)、患侧、脉管癌栓情况以及是否放疗方面的差异均无统计学意义(P>0.05);但在年龄、单独N分期(淋巴结转移情况)、TNM分期、手术方式、雌激素受体和孕激素受体状态、Ki-67表达水平、组织学类型、组织学分级、是否接受新辅助治疗及辅助化疗方面3组不同HER2表达水平乳腺癌患者间的差异均有统计学意义(P<0.05).生存分析结果显示:早期乳腺癌患者的预后情况可能与HER2表达水平无显著相关性,年轻早期乳腺癌患者的预后同样可能与HER2表达状态无统计学意义上的相关性.结论 不同HER2表达水平的乳腺癌患者在多项临床病理特征上存在差异,但这些差异并未显著影响患者的预后.特别是对于年轻早期乳腺癌,HER2表达水平对预后没有明显的影响.这提示在治疗和预后评估中,HER2状态可能并非决定性因素,需要综合考虑其他病理特征与治疗方法.
Clinicalpathological characteristics and prognostic analysis of young early breast cancer patients with low HER2 expression
Objective To compare the clinicopathological characteristics and prognosis of young early breast cancer patients with different human epidermal growth factor receptor 2(HER2)expression levels,and to analyze the clinicopathological characteristics and prognosis of young early breast cancer patients with low HER2 expression.Methods A total of 1 723 breast cancer patients who were treated in the Department of Breast Surgery of the First Affiliated Hospital of Xi'an Jiaotong University between June 2016 and June 2018 were collected and divided into three groups:HER2-negative,low-expression,and high-expression.The clinicopathological characteristics of the three groups were compared,and the relationship between HER2 expression and patients'prognosis was analyzed.Results There were 512 HER2-negative patients,748 HER2-low expression patients,and 463 HER2-high expression patients.The results of the clinical pathological characteristics analysis of the three groups of patients showed that there were no statistical differences in marital status,menopausal status,family history,single T stage(tumor size),single M stage(distant metastasis),affected side,vascular tumor thrombus,and radiotherapy in the three groups of breast cancer patients with different HER2 expression levels(P>0.05).However,there were statistical differences in age,Ki-67 expression level,N stage,TNM stage,surgical method,estrogen receptor and progesterone receptor status,histological type,histological grade,whether to receive neoadjuvant therapy and adjuvant chemotherapy in breast cancer patients with different HER2 expression levels(P<0.05).The results of survival analysis showed that the prognosis of early breast cancer patients may not be significantly correlated with the HER2 expression level,and the prognosis of young early breast cancer patients may also not be statistically correlated with the HER2 expression status.Conclusions Breast cancer patients with different HER2 expression levels differ in multiple clinicopathological characteristics,but these differences do not significantly affect the prognosis of the patients.Especially for early-stage breast cancer,HER2 expression levels do not seem to have a significant impact on prognosis.This suggests that HER2 status may not be a decisive factor in treatment and prognosis assessment,and other pathological characteristics and treatment methods need to be considered comprehensively.The prognosis of young breast cancer patients in early stage may also not be statistically correlated with HER2 expression status.

human epidermal growth factor receptor 2young early breast cancerclinicopathological characteristicsprognosis

朱丽喆、杜金穗、段程泷、于淑尧、南朝利、王彬、任予

展开 >

西安交通大学第一附属医院乳腺外科(西安 710061)

人表皮生长因子受体2 年轻早期乳腺癌 临床病理特征 预后

2024

中国普外基础与临床杂志
四川大学华西医院

中国普外基础与临床杂志

CSTPCD
影响因子:0.858
ISSN:1007-9424
年,卷(期):2024.31(9)
  • 4